131 related articles for article (PubMed ID: 24158080)
1. Volumetric-modulated arc therapy for a pelvic lymph node metastasis from prostate cancer: a case report.
von Eyben FE; Kangasmäki A; Kiljunen T; Joensuu T
Tumori; 2013; 99(3):e120-3. PubMed ID: 24158080
[TBL] [Abstract][Full Text] [Related]
2. [Reevaluation of MAB therapy and progress of endocrine therapy].
Klotz L; Payne H; Gillatt D; Keane T; Morris C; Akaza H; Hirao ; Akakura K; Fukagai T
Gan To Kagaku Ryoho; 2005 May; 32(5):705-28. PubMed ID: 15934164
[No Abstract] [Full Text] [Related]
3. Toxicity and outcome of pelvic IMRT for node-positive prostate cancer.
Müller AC; Lütjens J; Alber M; Eckert F; Bamberg M; Schilling D; Belka C; Ganswindt U
Strahlenther Onkol; 2012 Nov; 188(11):982-9. PubMed ID: 23053142
[TBL] [Abstract][Full Text] [Related]
4. Helical intensity-modulated radiotherapy of the pelvic lymph nodes with integrated boost to the prostate bed - initial results of the PLATIN 3 Trial.
Katayama S; Habl G; Kessel K; Edler L; Debus J; Herfarth K; Sterzing F
BMC Cancer; 2014 Jan; 14():20. PubMed ID: 24422782
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of long-term androgen suppression with bevacizumab and intensity-modulated radiation therapy (IMRT) in high-risk prostate cancer.
Vuky J; Pham HT; Warren S; Douglass E; Badiozamani K; Madsen B; Hsi A; Song G
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e609-15. PubMed ID: 22208976
[TBL] [Abstract][Full Text] [Related]
6. The effect of concurrent androgen deprivation and 3D conformal radiotherapy on prostate volume and clinical organ doses during treatment for prostate cancer.
Onal C; Topkan E; Efe E; Yavuz M; Arslan G; Yavuz A
Br J Radiol; 2009 Dec; 82(984):1019-26. PubMed ID: 19581310
[TBL] [Abstract][Full Text] [Related]
7. [Prostate carcinoma with squamous differentiation after combination endocrine therapy: a case report].
Nagashima T; Niiro M; Hirayama K; Date S; Okihara K; Mukaisho K
Hinyokika Kiyo; 2012 Aug; 58(8):457-60. PubMed ID: 23052274
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide.
Mason M; Maldonado Pijoan X; Steidle C; Guerif S; Wiegel T; van der Meulen E; Bergqvist PB; Khoo V
Clin Oncol (R Coll Radiol); 2013 Mar; 25(3):190-6. PubMed ID: 23257248
[TBL] [Abstract][Full Text] [Related]
9. Chemical castration and anti-androgens induce differential gene expression in prostate cancer.
Lehmusvaara S; Erkkilä T; Urbanucci A; Waltering K; Seppälä J; Larjo A; Tuominen VJ; Isola J; Kujala P; Lähdesmäki H; Kaipia A; Tammela TLj; Visakorpi T
J Pathol; 2012 Jul; 227(3):336-45. PubMed ID: 22431170
[TBL] [Abstract][Full Text] [Related]
10. Significance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasis.
Nozawa M; Hara I; Matsuyama H; Iki M; Nagao K; Nishioka T; Komura T; Esa A; Uejima S; Imanishi M; Uekado Y; Ogawa T; Kajikawa H; Uemura H
World J Urol; 2015 Sep; 33(9):1263-8. PubMed ID: 25354720
[TBL] [Abstract][Full Text] [Related]
11. [8-month neoadjuvant hormonal therapy before radical prostatectomy for high-risk prostate cancer].
Tabata K; Satoh T; Matsumoto K; Fujita T; Irie A; Iwamura M; Yanagisawa N; Matsuda D; Muramoto M; Kadowaki K; Suyama K; Shoji K; Koh H; Kawakami T; Okayasu I; Egawa S; Baba S
Nihon Hinyokika Gakkai Zasshi; 2006 Jul; 97(5):712-8. PubMed ID: 16898594
[TBL] [Abstract][Full Text] [Related]
12. High-dose radiotherapy plus prolonged hormone therapy in CT2-3 prostatic carcinoma: is it useful?
Cellini N; Pompei L; Fortuna G; Ammaturo MV; De Paula U; Luzi S; Mattiucci GC; Morganti AG; Digesù C; Rosetto ME; Palloni T; Petrongari MG; Gentile P; Deodato F; Valentini V
Tumori; 2004; 90(2):201-7. PubMed ID: 15237583
[TBL] [Abstract][Full Text] [Related]
13. Safe usage of bicalutamide and goserelin in a male patient with acute intermittent porphyria and prostate cancer.
Sofie Lichtwarck Bjugn F; Storjord E; Kristensen RM; Brekke OL
Scand J Urol; 2019; 53(2-3):171-173. PubMed ID: 30714461
[No Abstract] [Full Text] [Related]
14. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
[TBL] [Abstract][Full Text] [Related]
15. [Radical retropubic prostatectomy for prostate cancer with pelvic lymph node metastasis].
Liu DY; Hu S; Zhou YF; He HC; Yu JS; Wang J; Xia WM; Tang Q; Wang MW; Zhou WL
Zhonghua Nan Ke Xue; 2017 Nov; 23(11):982-986. PubMed ID: 29738162
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic performance and safety of NMK36 (trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid)-PET/CT in primary prostate cancer: multicenter Phase IIb clinical trial.
Suzuki H; Inoue Y; Fujimoto H; Yonese J; Tanabe K; Fukasawa S; Inoue T; Saito S; Ueno M; Otaka A
Jpn J Clin Oncol; 2016 Feb; 46(2):152-62. PubMed ID: 26732384
[TBL] [Abstract][Full Text] [Related]
17. Intermittent versus continuous androgen deprivation in prostate cancer.
Hussain M; Tangen CM; Berry DL; Higano CS; Crawford ED; Liu G; Wilding G; Prescott S; Kanaga Sundaram S; Small EJ; Dawson NA; Donnelly BJ; Venner PM; Vaishampayan UN; Schellhammer PF; Quinn DI; Raghavan D; Ely B; Moinpour CM; Vogelzang NJ; Thompson IM
N Engl J Med; 2013 Apr; 368(14):1314-25. PubMed ID: 23550669
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years.
Suardi N; Gandaglia G; Gallina A; Di Trapani E; Scattoni V; Vizziello D; Cucchiara V; Bertini R; Colombo R; Picchio M; Giovacchini G; Montorsi F; Briganti A
Eur Urol; 2015 Feb; 67(2):299-309. PubMed ID: 24571959
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study.
Corn PG; Song DY; Heath E; Maier J; Meyn R; Kuban D; DePetrillo TA; Mathew P
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):540-5. PubMed ID: 23541810
[TBL] [Abstract][Full Text] [Related]
20. Targeted salvage lymphadenectomy in patients treated with radical prostatectomy with biochemical recurrence: complete biochemical response without adjuvant therapy in patients with low volume lymph node recurrence over a long-term follow-up.
Winter A; Henke RP; Wawroschek F
BMC Urol; 2015 Feb; 15(1):10. PubMed ID: 25881245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]